$20M for miRagen? It's a Cinch
April 25, 2012- Share:
miRagen Therapeutics has racked up $20 million in Series B financing from lead investor Remeditex Ventures and its existing band of investors, which includes Atlas Venture, Boulder Ventures, Amgen Ventures and Broadview Ventures. The biopharma company will use the funds to advance the development of its microRNA-based cardiovascular and muscle disease therapeutics.
Investors
Remeditex Ventures
(lead)
- Share:
-
-
-
-